Information Provided By: 
Fly News Breaks for October 9, 2018
PCRX
Oct 9, 2018 | 06:03 EDT
Piper Jaffray analyst David Amsellem raised his price target for Pacira Pharmaceuticals to $51 after increasing his estimates for Exparel. Recent monthly sales data make it clear that the nerve block label expansion is having a real impact, Amsellem tells investors in a research note. The analyst believes Pacira is well positioned to deliver Exparel sales growth that is "solidly in the double digits for the foreseeable future." He reiterates an Overweight rating on the shares.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
